Maintrac® Companion Diagnostics
Maintrac Companion Diagnostics features world-class biomarker analysis. Information on the genetic activity of a person's cancer assists practitioners in gaining an understanding of the unique behaviour of a person's cancer cells. The biomarkers that are available for testing include: Estrogen Receptor, HER2/neu, Androgen Receptor, VEGF Receptor, EGF Receptor, ki-67, PLAP and BRaf mutations. This test can only be requested addition to the CTC-count test. Other biomarkers may be available upon request. The best way to monitor cancer activity and long-term effectiveness of treatment is via a single CTC Count test every 3-6 months. Patient information hand-outs or your clinic are available upon request by phoning 1300 282 482.
This test can only be ordered in addition to a CTC Count Test, which is $630 in Australia and $715 in New Zealand.
ER, AR, Ki-67, PLAPR, PD-L1: $310
HER2/neu, EGFR, VEGFR, P53: $360
Other biomarkers may be available – please contact Genostics to discuss price and availability.
Prices are in AUD and subject to change without notice
ORDER A TEST
Complete instructions for ordering a test, blood sample collection and dispatch can be found here
Tests can only be ordered by registered, certified Healthcare Practitioners.
To order, please download and complete a test request, and send it to Genostics via email (firstname.lastname@example.org) or fax (+61 2 8088 7097)
Companion Diagnostics - Patient Information
NEW! Poster: Somatic mutations of the EGFR, KRAS and BRAF genes: homogeneitiy in single cells from cell lines and heterogeneity in Circulating Epithelial Tumor Cells (CETCs) as determined using cobas® z480 analyzer (2014) ...View this poster This poster was awarded 'Best Poster' at the Clinical Oncology Society of Australia annual conference in Melbourne, 2014
NEW! Publication: Behaviour of Circulating Epithelial Tumor Cells (CETCs) and FISH (Fluorescence in situ hybridisation) of Epidermal Growth Factor Receptor (EGFR -gene amplification in lung cancer patients during the course of therapy ...Read this publication
Publication: Efficacy of control of therapy using Circulating Epithelial Tumor Cells (CETCs) as "Liquid Biopsy": trastuzumab in HER2/neu-positive breast carcinoma (2011) ...Read this publication
Publication: Insulin-like Growth Factor Receptor I (IGR-IR) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) are expressed on the Circulating Epithelial Tumor Cells of breast cancer patients ...Read this publication
Publication: An increase in cell number at the completion of therapy may develop as an indicator of early relapse (2008) ...Read this publication